DCOY

Business Context and Reporting Period

Company: Salarius Pharmaceuticals, Inc. (Note: The input metadata referenced Decoy Therapeutics, but the filing text is for Salarius Pharmaceuticals, which is entering a merger with Decoy).

Reporting Period: Fiscal year ended December 31, 2024.

Business Overview: Salarius is a clinical-stage biopharmaceutical company focused on oncology therapeutics targeting dysregulated gene expression. Its pipeline includes SP-3164 (targeted protein degrader) and seclidemstat/SP-2577 (targeted protein inhibitor). The company has no approved products and has never generated revenue from product sales.

Strategic Status: On January 10, 2025, Salarius entered into a Merger Agreement with Decoy Therapeutics Inc. The transaction is structured as a stock-for-stock merger where Decoy stockholders would own approximately 85.9% of the combined company. The merger is contingent upon a "Qualified Financing" of at least $6.0 million and continued Nasdaq listing.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Reduction in R&D Spend: R&D expenses decreased by approximately $6.4 million (89%) year-over-year, driven by a cost-saving plan implemented in late 2023 and the curtailment of the SP-2577 Phase 1/2 clinical trial for Ewing sarcoma.
• Improved Net Loss: Net loss narrowed by $6.97 million to $5.58 million, primarily due to reduced operating expenses.
• Cash Burn Reduction: Net cash used in operating activities decreased by $8.3 million compared to the prior year.
• Equity Issuances: In 2024, the company raised approximately $1.53 million through equity issuances. Subsequent to year-end (Jan-Mar 2025), the company raised an additional $0.74 million under an ELOC agreement.
• Warrant Cancellation: In January 2025, the company paid $350,000 to cancel a warrant exercisable for 454,546 shares.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: The filing states substantial doubt exists regarding the company's ability to continue as a going concern. Management believes current cash resources ($2.43 million) are sufficient only into the later part of the second quarter of 2025.
• Merger Dependency: The company's survival and future operations are heavily dependent on the successful consummation of the merger with Decoy Therapeutics. If the merger fails, the board may pursue dissolution and liquidation.
• Financing Requirement: The merger closing is conditioned on raising a minimum of $6.0 million in a "Qualified Financing."
• Nasdaq Listing Risks: The company is not in compliance with Nasdaq's Stockholders' Equity Requirement (equity of $1.5 million vs. $2.5 million required) and expects a delisting notice. Additionally, the stock price has traded below the $1.00 minimum bid price, posing an immediate delisting risk if not corrected.
• Clinical Trial Status: The SP-2577 trial for Ewing sarcoma was closed. The MD Anderson-sponsored trial for myelodysplastic syndromes was placed on partial clinical hold in July 2024 due to an adverse event but resumed enrollment in February 2025.
• Management Commentary: The company has reduced its workforce to two full-time employees and is relying on consultants to manage operations and the merger process.

Investor Verification Checklist

• Merger Closing Conditions: Verify the status of the $6.0 million Qualified Financing required to close the Decoy merger.
• Nasdaq Compliance: Monitor the company's ability to regain compliance with Nasdaq listing standards (minimum bid price and stockholders' equity) to avoid delisting.
• Liquidity Runway: Confirm the sufficiency of cash reserves ($2.43 million) to fund operations through Q2 2025 if the merger is delayed.
• Stockholder Dilution: Review the final exchange ratio and the impact of the Qualified Financing on legacy Salarius stockholder ownership (currently estimated at ~14.1% pre-financing).
• Clinical Trial Safety: Monitor the status of the SP-2577 trial at MD Anderson following the lifting of the clinical hold.